Abstract
1. We compared the effects of two doses (5 and 10 mg) of oral pimobendane (UD-CG 115) on haemodynamics in eight patients suffering from chronic congestive heart failure. The two doses were given according to a randomized cross-over double-blind protocol; haemodynamics and plasma levels of pimobendane and its main metabolite UD-CG 212, were determined 1, 2, 3, 5, 7, 9, 11 and 12 h after each dose. 2. Both doses significantly improved the left and right ventricular functions of these patients, with a peak action 3 h after drug intake and long duration (more than 12 h). A significant dose-effect relationship was observed only for pulmonary wedge pressure and right atrial pressure. Significant correlations were found between UD-CG 212 plasma levels and cardiac index (r = 0.54, P less than 0.05), and pulmonary wedge pressure (r = 0.74, P less than 0.001); no correlation was found between these haemodynamic variables and pimobendane plasma levels. 3. One patient developed a transient drop in blood platelets together with a cutaneous rash, while three others had a transient and mild decrease of thrombocytes. 4. In conclusion, pimobendane improved right and left ventricular functions in severe heart failure. Both doses (5 and 10 mg) were effective. The higher dose induced marked improvement of the haemodynamic variables but the difference between doses was only significant for right atrial and pulmonary wedge pressures.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell W. R. Editorial: Thrombocytopenia occurring during heparin therapy. N Engl J Med. 1976 Jul 29;295(5):276–277. doi: 10.1056/NEJM197607292950511. [DOI] [PubMed] [Google Scholar]
- Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986 Feb 6;314(6):349–358. doi: 10.1056/NEJM198602063140605. [DOI] [PubMed] [Google Scholar]
- Likoff M. J., Weber K. T., Andrews V., Janicki J. S., Sutton M. S., Wilson H., Rocci M. L., Jr Amrinone in the treatment of chronic cardiac failure. J Am Coll Cardiol. 1984 May;3(5):1282–1290. doi: 10.1016/s0735-1097(84)80189-8. [DOI] [PubMed] [Google Scholar]
- Rüegg J. C. Effects of new inotropic agents on Ca++ sensitivity of contractile proteins. Circulation. 1986 Mar;73(3 Pt 2):III78–III84. [PubMed] [Google Scholar]
- Shah P. K., Amin D. K., Hulse S., Shellock F., Swan H. J. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. Circulation. 1985 Feb;71(2):326–331. doi: 10.1161/01.cir.71.2.326. [DOI] [PubMed] [Google Scholar]
- Verdouw P. D., Hartog J. M., Duncker D. J., Roth W., Saxena P. R. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol. 1986 Jul 15;126(1-2):21–30. doi: 10.1016/0014-2999(86)90733-8. [DOI] [PubMed] [Google Scholar]